Note: Descriptions are shown in the official language in which they were submitted.
CA 02349593 2001-05-04
WO 00/Z6668 PCTNS99/26226
5100 PROTEINS AND AUTOANTIBODIES
AS SERUM MARKERS FOR CANCER
SPECIFICATION
1. INTRODU('tTION
The present invention relates to screening methods for diagnosis and
prognosis of cancer in a subject by means of detecting increased levels of
5100
protein in sera and other biological fluids of the subject. The method of the
invention
can also be used to identify subjects at risk for developing cancer. The
method of the
invention involves the use of subject derived serum samples, or other
biological fluid
samples, to determine the occurrence and level of specific circulating S 100
proteins.
The invention also provides screening methods for diagnosis, prognosis, or
susceptibility to cancer in a subject by means of detecting the presence of
serum
autoantibodies to specific S 100 protein antigens in sera from subj ects. The
present
invention further provides for kits for carrying out the above described
screening
methods. Such kits will be used to screen subjects for increased levels of S
100
protein, or for the .detection of autoantibodies to S 100 proteins, as a
diagnostic,
predictive or prognostic indicator of cancer. The invention is demonstrated by
way of
example in which increased levels of specific S 100 proteins were identified
in serum
samples derived from subjects with cancer. In addition, elevated levels of
circulating
autoantibodies reactive against several S 100 proteins were detected in the
sera of
cancer subjects.
2. BACKGROUND OF THE INVENTION
A number of cellular proteins have been demonstrated to occur at
increased levels in body fluids of subjects with different types of cancer.
The
increased levels of such proteins in cancer subjects provide diagnostic and
prognostic
assays for the presence of cancer. For example, elevated serum levels of
prostate
specific antigen (PSA) is frequently used as an indicator of the presence of
prostate
CA 02349593 2001-05-04
WO 00/26668 PCTNS99/26226
2
cancer in subjects. The occurrence of antibodies to tumor derived proteins as
in the
case of mutant p53 has also been noted to occur in some cancers. However,
there is
little knowledge that allows prediction of which proteins in tumors may be
antigenic
or may occur at increased levels in body fluids.
S S 100 proteins are low-molecular-weight calcium binding proteins that
are believed to play an important role in various cellular processes such as
cytoskeletaI/membrane interactions, cell division and differentiation. The S
100 family
of proteins consists of at least 17 family members and the genes encoding this
family
of proteins have been localized to human chromosomes 1q21. The 5100 proteins
possess a characteristic EF-hand domain which binds calcium with high
affinity. The
designation S 100 protein refers to the original protein; other S 100 proteins
are
referred to specifically as, for example, S 100-A7, S 100-A8, etc.
Two specific S 100 proteins, S 100-A8 and S 100-A9, also referred to as
myeloid related protein-8 (MRP-8) and myeloid related protein-14(MRP-14), are
composed of two distinct EF-hands flanked by hydrophobic regions at either
terminus
separated by a central hinge region. 5100-A8 has been demonstrated to mediate
chemotactic activity on macrophages and a peptide encoded by the hinge region
(between the two EF-hands) has been shown to specifically mediate this effect.
5100-
A8 and S 100-A9 have both been shown to be secreted from ganulocytes and
monocytes, although, it is presently unclear how these proteins are secreted
as they do
not possess a classical signal peptide. One possibility is that calcium
binding may
expose a hydrophobic domain which could allow an interaction with the
membrane,
thereby resulting in secretion of the molecules. Both S 100-A8 and S 100-A9
homodimerize and heterodimerize with each other, thus forming complexes of
various
molecular weights. An antibody against the cystic fibrosis antigen (an epitope
formed
by heterodimerization of S 100-A8 and S 100-A9) also will react positively
against a 14
kDa antigen which has been shown to be S 100-A9.
The expression of S 100 protein has been evaluated in a variety of
disorders. For example, S 100 proteins have been evaluated as serum markers
for
subjects with inflammatory diseases, including ulcerative colitis, Crohn's
disease, and
as serum markers for subjects with infectious diseases including AIDs and
malaria and
CA 02349593 2001-05-04
WO 00/Z6668 PCT/US99I25226
for subjects with hematological disease. Evidence has accumulated that
indicates that
some S 100 proteins can alter cellular invasion and metastatic spread of
cancer. For
example, S 100 protein is expressed in dendritic cells in human transitional
cell
carcinoma of the bladder and the invasive potential of these tumors has been
found to
correlate with the presence of S 100 protein expressing cells (moue et al.,
1993,
Virchows Arch A 422: 351-355). Additionally, the expression of S100A4
correlates
with the in vitro invasive potential of glioma cells (Merzak, et al., 1994,
Neuropathol
App. Neurobiol. 20: 614-619).
Expression of S 100 proteins has also been evaluated as a serum
marker for melanoma {Henze et al. 199, Dermatology 194:208-212; Buer et al.,
1997,
Brit. J. Cancer 75:1373-1376; Sherbet et al. 1998, Anticancer Research 18:2415-
2422). However, S 100 proteins have not been previously considered as serum
markers for cancer in general, nor that their detectablity in serum might have
prognostic or therapeutic significance in cancer. Additionally, there have not
been
prior findings of auto-antibodies to S 100 proteins in cancer.
3. SUMMARY OF THE INVENTION
It is an object of the present invention to provide methods for the
diagnostic and prognostic evaluation of cancer, for the identification of
subjects
possessing a predisposition to cancer, and for monitoring patients undergoing
treatment of cancer, based on the detection of increased levels of S 100
protein
expression in biological fluid samples of subjects. The invention provides
methods
for detecting overexpression of individual S 100 proteins and/or
overexpression of
groups of S 100 proteins as a diagnostic or prognostic indicator of cancer.
The invention comprises assays developed to detect the level of S 100
proteins in a subject's serum sample. Such assays include immunoassays wherein
the
S 100 proteins are detected by their interaction with anti-S 100 specific
antibodies. For
example, S 100 antibodies or fragments of antibodies may be used to
quantitatively
detect the presence of S 100 proteins in a serum sample.
The invention further relates to diagnostic evaluation and prognosis of
cancer by detecting autoantibodies to 5100 protein antigens in the serum of
subjects
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
4
with cancer or with precancerous lesions. The detection of increased serum
levels of
autoantibodies to S 100 proteins constitutes a novel strategy for screening,
diagnosis
and prognosis of cancer.
The present invention relates to the use of the S 100 protein antigens in
immunoassays designed to detect the presence of serum autoantibodies to the S
100
protein antigens. Such immunoassays can be utilized for diagnosis and
prognosis of
cancer. In accordance with the invention, measurement of S 100 autoantibody
levels
in a subject's serum can be used for the early diagnosis of cancer. Moreover,
the
monitoring of serum autoantibody levels can be used prognostically to stage
progression of the disease.
The invention also relates to the use of S 100 proteins as antigens to
immunize patients suffering from diseases characterized by the expression of
the S 100
protein antigens. Stimulation of an immunological response to such antigens,
is
intended to elicit a more effective attack of tumor cells; such as 'inhibiting
tumor cell growth or facilitating the killing of tumor cells. The
identification of
autoantibodies to S 100 protein antigens associated with particular cancers
provides a
basis for immunotherapy of the disease.
The invention further provides for pre-packaged diagnostic kits which
will be conveniently used in clinical settings, to diagnose patients having
cancer or a
predisposition to developing cancer. The kits will also be utilized to monitor
the
efficiency of compounds used for treatment of cancer.
In a specific embodiment of the invention described herein, an increase
in the level of specific S 100 proteins was detected in serum samples derived
from
subjects with lung cancer as well as colon cancer. Additionally, a number of S
100
family members were shown to be secreted from breast cancer cells indicating
that
detection of these specific proteins in body fluid samples can be used for
diagnosis
and prognosis of subjects with breast cancer. In yet another specific
embodiment,
autoantibodies against specific S 100 proteins were detected in the serum of
subjects
with cancer. The finding that levels of S 100 proteins and S 100
autoantibodies are
increased in serum of cancer subjects provides a basis for development of
diagnostic
and prognostic methods as well as a means for monitoring the efficacy of
various
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26Z26
therapeutic treatments for cancer.
4. BRIEF DES~$;fPTION OF THE DRAWINGS
Figure 1 A-B. Two dimensional electrophoretic gel patterns of normal
colon (Figure lA) and a colon tumor (Figure 1B) from the same subject. The
location
5 of some of the S 100 proteins is identified with arrows. MRP-14 corresponds
to S 100-
A9 and MRP-8 corresponds to S 100-A8.
Figure 2. Two dimensional patterns of secreted proteins from breast
cancer cells identifying the location of S 100 proteins.
Figure 3. Detection of an protein band corresponding to S 100-A9 in
' serum of lung cancer subjects.
Figure 4A. Western blot of a lung cancer treated with a serum from a
subject with lung adenocarcinoma tumor.
Figure 4B. Western Blot of lung cancer treated with serum from a
normal subject.
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention achieves a highly desirable objective, namely
providing methods for the diagnostic and prognostic evaluation of subjects
with
cancer and the identification of subjects exhibiting a predisposition to
developing
cancer. The assays of the invention comprise methods designed to detect
increased
levels of S 100 protein, or the presence of S 100 autoantibodies, in serum or
other
biological fluids of a subject.
Specifically, the invention encompasses a method for diagnosis and
prognosis of cancer in a subject comprising:
(a) detecting at least one S 100 protein selected from the group
consisting of S 100-AG, S 100-A7, S 100-A8 and S 100-A9 in a
biological fluid sample derived from a subject; and
(b) comparing the level of protein detected in the subject's sample
to the level of protein detected in a control sample,
wherein an increase in the level of S100 protein detected in the subject's
sample as
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
6
compared to control samples is an indicator of a subject with cancer or at
increased
risk for cancer
A wide variety of protein mixtures that may contain S 100 proteins can
be prepared or assayed for the level of protein expression. In a preferred
embodiment
sera and other biological fluids in which secreted proteins localize can be
used to
screen for increased levels of protein expression.
The present invention encompasses a method for diagnosis and
prognosis of a subject with cancer, comprising:
(a) contacting a serum sample derived from a subject with a sample
containing S 100 protein antigens under conditions such that a
specific antigen-antibody binding can occur; and
(b) detecting the presence of immunospecific binding of
autoantibodies present in the subject's serum sample to the
S 100 protein,
wherein the presence of immunospecific binding of autoantibodies indicates the
presence of cancer.
In a specific embodiment of invention, any member of the S 100 protein
family can be purified and utilized to screen a subject's serum for the
presence of
circulating autoantibodies to such protein antigens, by means of sensitive and
rapid
immunoadsorbent assays or by other procedures.
The present invention also provides for kits for carrying out the above-
described methods. The methods can be performed, for example, by utilizing pre-
packaged diagnostic kits comprising at least a reagent for detecting S 100
protein such
as an anti-S 100 antibody. Alternatively, the diagnostic kits will comprise an
S 100
peptide for detection of S 100 autoantibodies in a subject derived sample.
The present invention is based on the discovery that levels of S 100
proteins in serum are increased in subjects with cancer such as lung cancer or
colon
cancer. In addition, breast cancer cells were demonstrated to secrete an S 100
protein
thus indicating that detection of circulating S 100 proteins can be used in
methods for
diagnostic and prognostic evaluation of breast cancer subjects. Additionally,
increased levels of circulating autoantibodies reactive against S 100 proteins
were
CA 02349593 2001-05-04
WO OOI26668 PCTNS99/26226
7
detected in the serum of cancer subjects.
5.1. ASSAYS FOR DETECTION OF S 100 EXPR SESE SION
In accordance with the invention, measurement of levels of S 100
proteins in serum or body fluids can be used for the early diagnosis of
diseases such as
cancer. Moreover, the monitoring of S 100 protein levels can be used
prognostically to
stage the progression of the disease and to evaluate the efficacy of compounds
used to
treat a cancer subject.
The detection of 5100 proteins in a body fluid from a subject can be
accomplished by any of a number of methods. Preferred diagnostic methods for
the
detection of S 100 proteins in the serum of a patient can involve, for
example,
immunoassays wherein S 100 proteins are detected by their interaction with an
S 100
specific antibody. Antibodies useful in the present invention can be used to
quantitatively or qualitatively detect the presence of S 100 peptides. In
addition,
reagents other than antibodies, such as, for example, polypeptides that bind
specifically to S 100 proteins can be used in assays to detect the level of S
100 protein
expression.
Immunoassays to be used in the practice of the invention include but
are not limited to assay systems using techniques such as Western blots,
radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich"
immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion
precipitin reactions, immunodiffusion assays, agglutination assays, complement
fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A
immunoassays, to name but a few.
A biological sample which may contain S 100 proteins, such as serum
or other biological fluids in which secreted proteins can localize, is
obtained from a
subject suspected of having a particular cancer or risk for cancer.
Immunoassays for
detecting expression of S 100 protein typically comprise contacting the
biological
sample, such as a serum sample derived from a subject, with an anti-S100
antibody
under conditions such that specific antigen-antibody binding can occur, and
detecting
or measuring the amount of any immunospecific binding by the antibody. In a
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
specific aspect, such binding of antibody, for example, can be used to detect
the
presence and increased expression of S 100 proteins wherein the detection of
increased
expression of S 100 proteins is an indication of a diseased condition. The
levels of
S 100 protein in a serum sample are compared to norms established for normal
individuals and for subjects with a variety of non-cancerous or pre-cancerous
disease
states.
In an embodiment of the invention, the biological sample, such as a
serum sample is brought in contact with a solid phase support or carrier, such
as
nitrocellulose, for the purpose of immobilizing any proteins present in the
sample.
The support is then washed with suitable buffers followed by treatment with
detectably labeled S 100 specific antibody. The solid phase support is then
washed
with the buffer a second time to remove unbound antibody. The amount of bound
antibody on the solid support is then determined according to well known
methods.
Those skilled in the art will be able to determine optional assay conditions
for each
determination by employing routine experimentation.
One of the ways in which S 100 antibodies can be detectably labeled is
by linking the antibody to an enzyme, such as for use in an enzyme immunoassay
(EIA) (Volley, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978,
Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication,
Walkersville, MD; Volley, A., et al., 1978, J. Clin. Pathol. 31:507-520;
Butler, J.E.,
1981, Meth. Enzymol. 73:482-523). The enzyme which is bound to the antibody
will
react with an appropriate substrate, preferably a chromogenic substrate, in
such a
manner as to produce a chemical moiety that can be detected, for example, by
spectrophotometric, fluorimetric,or by visual means. Enzymes that can be used
to
detectable label the antibody include, but are not limited to, horseradish
peroxidase
and alkaline phosphatase. The detection can also be accomplished by
colorimetric
methods that employ a chromogenic substrate for the enzyme.
Detection of S 100 antibodies may also be accomplished using a variety
of other methods. For example, by radioactively labeling the antibodies or
antibody
fragments, it is possible to detect S 100 protein expression through the use
of a
radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
9
Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques,
The Endocrine Society, March 1986). The radioactive isotope can be detected by
such
means as the use of a gamma counter or a scintillation counter or by
autoradiography.
The antibody may also be labeled with a fluorescent compound.
Among the most commonly used fluorescent labeling compounds are fluorescein
isothiocyanate, rhodamine, phycoerythrin and fluorescamine. Likewise, a
bioluminescent compound may be used to label the S 100 antibody. The presence
of a
bioluminescence protein is determined by detecting the presence of
luminescence.
Important bioluminescence compounds for purposes of labeling are luciferin,
luciferase and aequorin.
In a specific embodiment of the invention, expression levels of S 100
proteins in biological samples can be analyzed by two-dimensional gel
electrophoresis. Methods of two-dimensional electrophoresis are known to those
skilled in the art. Biological samples, such as serum samples, are loaded onto
electrophoretic gels for isoelectric focusing separation in the first
dimension which
separates proteins based on charge. A number of first-dimension gel
preparations may
be utilized including tube gels for carrier ampholytes-based separations or
gels strips
for immobilized gradients based separations. After first-dimension separation,
proteins are transferred onto the second dimension gel, following an
equilibration
procedure and separated using SDS PAGE which separates the proteins based on
molecular weight. When comparing serum samples derived from different
subjects,
multiple gels are prepared from individual serum samples.
Following separation, the proteins are transferred from the two-
dimensional gels onto membranes commonly used for Western blotting. The
techniques of Western blotting and subsequent visualization of proteins are
also well
known in the art (Sambrook et al, "Molecular Cloning, A Laboratory Manual",
2"a
Edition, Volume 3, 1989, Cold Spring Harbor). The standard procedures may be
used, or the procedures may be modified as known in the art for identification
of
proteins of particular types, such as highly basic or acidic, or lipid
soluble, etc. (See
for example, Ausubel, et al., 1989, Current Protocols in Molecular Biology,
Green
Publishing Associates and Wiley Interscience, N.Y.). Antibodies that bind to
the
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
S 100 proteins are utilized in an incubation step, as in the procedure of
Western blot
analysis. A second antibody specific for the first antibody is utilized in the
procedure
of Western blot analysis to visualize proteins that reacted with the first
antibody.
The detection of S 100 protein expression can also be used to monitor
5 the efficacy of potential anti-cancer compounds during treatment. For
example, the
level of S 100 protein expression can be determined before and during
treatment. The
efficacy of the compound can be followed by comparing S 100 expression
throughout
the treatment. Compounds exhibiting efficacy are those which decrease the
level of
5100 protein expression as treatment with the compound progresses.
10 The present invention is demonstrated by way of example wherein
elevated levels of an S 100 protein was detected in serum samples derived from
cancer
subjects. In particular, increased levels of S 100-A9 were detected in serum
samples
derived from colon and lung patients. In addition, S 100-A7 and S 100-A8
proteins
were shown to be secreted by breast cancer cells, which provide the basis for
diagnostic and prognostic assays for breast cancer. The detection and/or
quantitative
measurement of S 100 proteins in serum or other body fluids can be used in
screening
of subjects who are at risk for developing certain types of cancers or other
proliferative disorders in which the S 100 proteins are over expressed. In
addition,
qualitative differences in the pattern of occurrence in serum or biological
fluids of
different members of the 5100 family of proteins can be used as a screening,
diagnostic or prognostic indicator of cancer or cancer risk.
5.2. ASSAYS FOR DETECTION OF ANTI-S 100 AUTOANTIBODIES
The present invention provides diagnostic and prognostic methods for
diseases such as cancer based on detection of circulating 5100 autoantibodies
in a
subject. The method is validated by the use of a biological sample from a
subject with
cancer and from controls, without cancer. A biological sample which may
contain
autoantibodies, such as serum, is obtained from a subject suspected of having
a
particular cancer or suspected of being predisposed to developing cancer. A
similar
body fluid is obtained from a control subject that does not have cancer.
CA 02349593 2001-05-04
WO 00126668 PC1YUS99/26226
11
in accordance with the invention, measurement of autoantibodies
reactive against the 5100 protein antigens can be used for the early diagnosis
of
diseases such as cancer. Moreover, the monitoring of autoantibody levels can
be used
prognostically to stage the progression of the disease. The detection of
autoantibodies
in a serum sample from a patient can be accomplished by any of a number of
methods.
Such methods include immunoassays which include, but are not limited to, assay
systems using techniques such as Western blots, radioimmunoassays, ELISA
(enzyme
linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation
assays, precipitin reactions, gel diffusion precipitin reactions,
immunodiffusion
assays, agglutination assays, complement fixation assays, immunoradiometric
assays,
fluorescent immunoassays, protein A immunoassays, to name but a few.
Such an immunoassay is carried out by a method comprising
contacting a serum sample derived from a subject with a sample containing the
S100
protein antigens under conditions such that specific antigen-antibody binding
can
occur, and detecting or measuring the amount of any immunospecific binding by
the
autoantibody. In a specific aspect, such binding of autoantibody by tissue
sections, for
example, can be used to detect the presence of autoantibody wherein the
detection of
autoantibody is an indication of a diseased condition. The levels of
autoantibodies in a
serum sample are compared to the levels present in an analogous serum sample
from a
subject not having the disorder.
The immunoassays can be conducted in a variety of ways. For
example, one method to conduct such assays involves anchoring of S 100 protein
onto
a solid support and detecting anti-S 100 antibodies specifically bound
thereto. The
S 100 proteins to be utilized in the assays of the invention can be prepared
via
recombinant DNA techniques well known in the art. For example, in instances
where
the nucleotide sequence of a DNA encoding an S 100 protein is available, the
DNA
can be genetically engineered into an appropriate expression vector for large
scale
preparation of S 100 protein. It may be advantageous to engineer fusion
proteins that
can facilitate labeling, immobilization or detection of the S 100 protein.
See, for
example, the techniques described in Sambrook et al., 1989, Molecular Cloning:
A
laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N. Y.
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
12
Alternatively, the S 100 protein may be purified from natural sources, e.g.,
purified
from cells, using protein separation techniques well known in the art. Such
purification techniques may include, but are not limited to molecular sieve
chromatography and/or ion exchange chromatography. In practice, microtitre
plates
S are conveniently utilized as the solid support for the S 100 proteins. The
surfaces may
be prepared in advance and stored.
The present invention is demonstrated by way of example wherein
elevated levels of circulating autoantibodies reactive against several S 100
protein
antigens were detected in the sera of cancer patients. 'The detection and/or
quantitative measurement of circulating anti-S 100 autoantibodies in serum can
be
used in screening of subjects who are at risk for cancer or other
proliferative disorders
in which S 100 proteins are expressed. Additionally, the present invention
further
relates to the use of the identified protein antigens as immunogens for
stimulation of
an host immune response against the tumor cells. It is expected that such an
approach
can be used as a method for inhibiting tumor cell growth or facilitating tumor
cell
killing in individuals with specific cancers.
5.3. IMMUNOTHERAPY
The invention also relates to the use of S 100 proteins as antigens to
immunize patients suffering from diseases characterized by the expression of
the S 100
protein antigens. Stimulation of an immunological response to such antigens,
is
intended to elicit a more effective attack of tumor cells; such as inter
inhibiting
tumor cell growth or facilitating the killing of tumor cells. The
identification of
autoantibodies to S 100 protein antigens associated with particular cancers
provides a
basis for immunotherapy of the disease.
The patient may be immunized with the S 100 protein antigens to elicit
an immune response which facilitates killing of tumor cells or inhibiting
tumor cell
growth. The S 100 protein antigens can be prepared using the methods described
above
for purification of proteins.
In an embodiment of the invention an immunogen comprising a
purified S100 protein antigen to which a patient with cancer has developed
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
13
autoantibodies, is used to elicit an immune response. For administration, the
S 100
protein antigen should be formulated with a suitable adjuvant in order to
enhance the
immunological response to the protein antigen. Suitable adjuvants include, but
are not
limited to mineral gels, e.g. aluminum hydroxide, surface active substances
such as
lysolecithin, plwonic polyols, polyanions, peptides, oil emulsions, and
potentially
useful human adjuvants such as BCG (bacilli Calmett-Guerin) and
(Corynebacterium
parvum). Many methods may be used to introduce the formulations derived above;
including but not limited to oral, intradermal, intramuscular,
intraperitoneal,
intravenous, and subutaneous.
5.4. KITS
The present invention further provides for kits for carrying out the
above-described assays. The assays described herein can be performed, for
example,
by utilizing pre-packaged diagnostic kits, comprising at least an S 100
peptide (for
detection of S 100 autoantibodies) or an S 100 antibody reagent (for detection
of S 100
protein), which can be conveniently used, e.g., in clinical settings to
diagnose
disorders such as cancer.
In a first series of nonlimiting embodiments, a kit according to the
invention comprises components for detecting and/or measuring human IgG
antibodies directed toward S 100 antigen. As one example, where the antibodies
are
detected and/or measured by enzyme linked immunoabsorbent assay (ELISA), such
components rnay comprise target antigen, in the form of ~at least one and
preferably a
plurality of different S 100 antigens or epitopes thereof, linked to a solid
phase, and a
means for detecting a human antibody antibody bound to target antigen. Such
means
for detection may be, for example, an antibody directed toward the constant
region of
human IgG (e.g., rabbit anti-human IgG antibody), which may itself be
detectably
labeled (e.g., with a radioactive, fluorescent, colorimetric or enzyme label),
or which
may be detected by a labeled secondary antibody (e.g., goat anti-rabbit
antibody).
In a second series of nonlimiting embodiments, a kit according to the
invention may comprise components which detect and/or measwe S 100 antigens in
the biological sample of a subject. For example, where S100 proteins are
detected
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
14
and/or measured by enzyme linked immunoabsorbent assay (ELISA), such
components may comprise an antibody directed to epitopes of the S 100 proteins
which can be used to detect and/or quantitate the level of S 100 expression in
the
biological sample. The antibody itself may be detectably labeled with a
radioactive,
flourescent, colorimetric or enzyme label. Alternatively, the kit may contain
a labeled
secondary antibody.
6. EXAMPLE: DETECTION OF A TUMOR ANTIGEN USING SERUM
ISOLATED FROM A SUBJECT HAVING CANCER
Subjects with lung and colon cancer were assayed for detection of
elevated levels of S 100 protein. Tumor tissue as well as normal tissue
control was
obtained from subjects with the following types of cancer: small cell lung
cancer,
squamous cell carcinoma of the lung, adenocarcinoma of the lung, esophageal
cancer
and Barrett's metaplasia, colon cancer, pancreatic cancer, breast cancer, and
prostate
cancer. An aliquot of whole tissue was solubilized using a solubilization
cocktail
prior to two-dimensional electrophoresis.
Solubilized proteins were loaded onto electrophoretic gels for
separation in the first dimension, based on charge. Two different first
dimension gel
preparations were utilized namely tube gels for carrier ampholyte based
isoelectric
focusing (IEF) and gels strips for immobilized pH gradients based separations
(IPG).
After the first dimension separation, proteins were transferred onto the
second
dimension gel, following an equilibration procedure and separated in the
second
dimension based on molecular weight. In some cases multiple gels were prepared
from individual serum samples. Proteins patterns were visualized by silver
staining
and analyzed for differences between normal and tumor tissue and/or for
differences
between different tumor types by means of a computerized matching process and
by
means of quantitation of spot intensities.
Many proteins occurred at an increased intensity in particular tumors
compared to controls. A set of four proteins occurred at an increased
intensity in
tumor patterns which were not detectable in controls. The quantitative data in
lung
cancer for one of the proteins which was later identified as S 100-A8 is given
in Table
CA 02349593 2001-05-04
WO 00/26668 PCTNS99/26226
I.
TABLEI
Detection of 5100-A8 in Tissue From Lung Tumor Patients
Patient Type Number Integrated
Intensity (Mean)
5 Tumor
Squamous 9 1.84
Adenocarcinoma 8 1.31
Small Cell 9 0.34
Normal Tissue 26 Not Detected
This protein was extracted from 2-D gels and subjected to amino acid
10 sequencing. It gave the N-terminal amino acid sequence MILTELEKALN, which
is
100% identical with the reported N-terminal amino acid sequence of the S 100-
A8
protein, found by searching protein databases. The other three proteins in the
set were
also identified as belonging to the S 100 family of proteins. Two were
consistent, with
S 100-A9 which has two translation initiation sites situated 4 amino acids
apart, and
15 one with Calgizzerin which is another S 100 related protein, as determined
by
reactivity with monoclonal antibodies and by comparison with published figures
of
two-dimensional protein separations. The location of these proteins in 2-D
patterns of
different tumor types is provided in Figures 1 and 2.
A commercially available antibody against S 100-A9
(DAKO;Carpinteria, CA) was utilized for immunohistochemistry and for Western
blotting. Immunohistochemistry on sections of tumor tissue and corresponding
normal tissue from the same subject with lung cancer was done. The analyzed
tissue
sections revealed minimal S 100-A9 immunoreactivity in the normal lung tissue.
The
observed increase in reactivity in the tumor tissue was attributed to the
presence of
infiltrative cells. There was also marked immunoreactivity in the area of
normal
tissue immediately adjacent to the tumor, resulting from infiltrative cells
(i.e.,
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
16
ganulocytes, monocytes and/or macrophage) recruited to the tumor.
An assay was performed to determine whether the S 100-A9 antibody
would recognize a specific band in the serum of tumor subjects, at levels
greater than
that which might be present in the serum of normal individuals. Proteins
contained in
the serum of 14 lung tumor subjects and 14 normal individuals were separated
by one
dimensional gel electrophoresis, the proteins transferred to PVDF membranes
and
probed with a commercial antibody (DAKO;Carpinteria, CA) that is reactive
against
the S 100-A9 protein. Integrated intensity analysis of reactivity in a band
visualized at
14 kDa revealed markedly increased reactivity in the serum from tumor subjects
(n=14; mean intensity of 0.46) as compared to that in the serum from normal
individuals (n=14; mean intensity of 0.09) (Table II). Another band at 22 kDa
was
also observed in some tumors and was presumed to result from another
immunoreactive form of S 100 protein. Similar results were also observed with
serum
of subjects with colon cancer.
TABLE II
Analysis of MRP14 Detection in Serum From Lung Tumor Patients
Patient Type Stage Number Integrated
Intensity
(Mean)
Tumor All 14 0.46
Squamous I 4 0.65
Adenocarcinoma None 1 0.03
I 3 0.26
IIIA 2 0.42
Bronchoalveolar I 1 0.44
Small Cell None 2 0.65
Other (Met. Ovarian) None 1 0.01
Normal 14 0.09
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/26226
17
A major determinant of the potential of a protein synthesized by tumors
to be detected in serum and other biological fluids is its secreted nature.
The features
of a protein that determine whether it is secreted by cells remains poorly
understood.
Factors that affect secretory process may depend on the occurrence of post-
S translational modifications in the protein as well as the activation of
certain signaling
pathways. In order to facilitate the identification of secretory proteins, a
method has
been developed to purify proteins secreted by cultured tumor cells, visualize
the
proteins in two-dimensional gels by coomassie or silver staining and analyze
secreted
protein spots by N-terminal sequencing or by Mass Spectrometry of their
constituent
peptides. Using this process three members of the S 100 family were identified
as
secreted proteins in breast cancer. N-terminal sequencing of two secreted
proteins
identified them as MRP8 and MRP 14 based on the following sequences:
Amino Acid Sequence Identify
MLTELEKALN MRPB
MCKMSQECRN MRP14
Additionally, mass spectrometry identified S 1 OOA7 as a secreted
protein in breast cancer. Seven peptides masses obtained by mass spectrometry
matched expected peptide masses for S 100A7/These were: 1291.65; 1307.66;
1323.65; 1384.69; 1455.66; 1583.65; and 1711.91.
7. EXAMPLE: DETECTION OF AUTOANTIBODIES
SPECIFIC FOR S 100 PROTEINS IN THE SERA
Using the method of the present invention, sera from subjects with lung
cancer were screened for reactivity against S 100 proteins.
An aliquot of lung tumor tissue was solubilized in a urea cocktail (per
liter:BM area, 20 ml Nonidet P-40 surfectant, 20 ml of ampholytes (pH 3.5-10),
20m1
of 2-mercuptoethanol and 0.2mm of phenylmethylsulfonyl fluoride (PMSF) in
distilled demonize H20) and 40 micrograms of solubilized protein was loaded
onto a
carrier ampholyte based (pH 3.8) tube gel and separated in the first dimension
for
12,000 volt hours. Following an equilibrium step, the first dimension tube gel
was
CA 02349593 2001-05-04
WO 00/26668 PCT/US99/Z6226
18
loaded onto a cassette containing the second dimension gel. Electrophoresis in
the
second dimension was complete when the tracking dye present in the
equilibration
buffer reached the opposite end of the second dimension gel, in relation to
the first
dimension gel. Following electrophoresis the separated proteins were
transferred onto
S a polyvinylideme fluoride (PVDF) membrane (millipore). The membrane was
preincubated with a blocking buffer and subsequently incubated with serum
obtained
from a subject with lung adenocarcinoma, which was diluted 1:100 in the buffer
solution (Tris-buffered-saline containing .O1% Between 20 and 1.8 gm/100 ml
non-fat
dry milk), for 1 hr at room temperature. After three washes with a buffer
solution, the
membrane was incubated for 1 hr with a horseradish peroxidase conjugated
rabbit
anti-human antibody (available from Amersham). Reactive proteins were revealed
by
a chemiluminescent technique. The sera sample from the cancer subject was
found to
be reactive against a set of S 100 proteins identified by microsequencing as S
100-A9
and calgizzerin (Figure 4A-B).
The present invention is not to be limited in scope by the embodiments
disclosed in the examples which are intended as an illustration of one aspect
of the
invention, and any compositions or methods which are functionally equivalent
are
within the scope of this invention. Indeed, various modifications of the
invention in
addition to those shown and described herein will become apparent to those
skilled in
the art from the foregoing description. Such modifications are intended to
fall within
the scope of the claims. Various publications are cited herein, the contents
of which
are incorporated, by reference, in their entireties.
